LobbyingUltragenyx lobbying by quarter
Ultragenyx's latest lobbying report covers Q1 2024, at $30K. Its first report covers Q4 2023; the issues it reports most are Health Issues and Medicare/Medicaid.
Ultragenyx
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2023 | $39K | 1 |
| Q1 2024 | $30K | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$27K · 2 reports
- Medicare and Medicaid$27K · 2 reports
- Budget and appropriations$7,500 · 1 reports
- Medical research and clinical labs$7,500 · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
- Food & Drug Administration (FDA)1 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Hashemi Strategic Advisors | $69K | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/04/01for Q1 2024 | Hashemi Strategic Advisors | $30K |
| 24/01/22for Q4 2023 | Hashemi Strategic Advisors | $39K |
| 23/11/13for Q4 2023 | Hashemi Strategic Advisors | Under $5,000 |